Intralesional Bevacizumab Injection on Primary Pterygium
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate that intralesional injection of bevacizumab on
primary pterygium can reduce the corneal pterygium area, inflammation, redness and other
symptoms.